BRF2 and non-small cell lung carcinoma: In many cancers, such as esophageal squamous cell carcinoma, adrenocortical carcinoma, invasive breast carcinoma, NSCLC, bladder carcinoma, and sarcoma, BRF2 is often amplified and/or gained through copy number alterations (Supplementary Figure S1A).